About Us
OBiO Technology (Shanghai) Corp., Ltd. is a biopharmaceutical CDMO/CMO company founded in 2013 which currently has more than 380 employees, over a quarter of whom are educated to PhD and M.Sc level. In 2016, OBiO built its gene therapy manufacturing platform meeting regulatory requirements in China, Europe and the United States. The GMP platform offers holistic CDMO services across plasmid, adeno-associated virus, lentivirus, adenovirus, oncolytic viruses, and cell therapy products for scientists, research facilities, medical institutions, and pharmaceutical companies. In 2020, OBiO initiated construction of a 80,000sqm OBiO Intelli-M GMP manufacturing site in Shanghai to satisfy explosive global demand for gene therapy products. OBiO strives to become the leading gene therapy CDMO and a trustworthy partner for global biopharmaceuticals and biotech companies.
CDMO Services
In 2016, OBiO built its gene therapy manufacturing platform that meets the regulatory requirements in China, Europe and the United States. Our GMP platform offers holistic CDMO services across plasmid, adeno-associated virus, lentivirus, adenovirus, oncolytic viruses, and cell therapy products for scientists, research facilities, medical institutions, and pharmaceutical companies. Starting from 2020, OBiO has initiated the construction of the 80,000m2 OBiO Intelli-M GMP manufacturing site in Shanghai to satisfy the explosively growing global demand on gene therapy products, striving to become the leading gene therapy CDMO and the trustful partner for global biopharmaceuticals and biotech companies.
